Project Grant R01HL182099
Award Date 7/1/26
Completion Date 3/31/30
Dollars Obligated $680K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,902,974 Project Grant to The Washington University (Office of Sponsored Research Services) on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The research award, with an ultimate completion date of February 28, 2028, supports a mechanistic investigation into the pathways linking acute respiratory triggers to chronic muco-obstructive lung disease. The principal...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Washington University $761,782 under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, with completion targeted for July 31, 2029. This project grant funds basic and translational research investigating the loss of cilia maintenance mechanisms in acquired and genetic lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $788,478 Project Grant to the University of Texas Medical Branch at Galveston effective September 1, 2025, through June 30, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). This award funds basic research investigating how C-type lectin receptor (CLR) signaling, specifically through the macrophage galactose-type lectin (MGL/CLEC10A), regulates immune metabolism and...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Washington University a Project Grant of $764,681 under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 1, 2026 through January 31, 2030. This award funds mechanistic research investigating cardiac fibroblast biology and fibrotic responses in heart failure. The research deliverables include comprehensive characterization of a novel stem cell antigen-1-expressing cardiac...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Regents of the University of Michigan a $100,228 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective December 1, 2026, with a completion date of April 19, 2029. The research project, titled "Defining Mechanisms for Induction of Antibacterial Lung-Resident CD4 T Cells," focuses on identifying the biological mechanisms that drive the establishment of...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,705 Project Grant to The Washington University, Office of Sponsored Research Services, effective August 15, 2025, through July 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This award supports a five-year research and career development initiative led by Dr. Amit Bery focused on investigating how immunosuppressive neutrophils modulate alloimmune responses...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $694,754 Project Grant to The Washington University, Office of Sponsored Research Services, effective August 1, 2025, through May 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative focuses on developing a mechanism-based precision medicine approach for treating cardiomyopathies by connecting molecular and cellular contractile dysfunction to patient...
- Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Oregon Health & Science University a Project Grant of $109,076 under the Cardiovascular Diseases Research program (CFDA 93.837) on March 18, 2026, with completion targeted for September 16, 2029. This research initiative focuses on spatial immunophenotyping of Mycobacterium tuberculosis (MTB) bacilli and secreted virulence factors within tuberculosis granulomas—the characteristic immune microenvironments that...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 (Cardiovascular Diseases Research) awarded $233,250 to The Washington University in St. Louis on June 15, 2026, with completion targeted for May 31, 2028. This Project Grant funds research investigating the mechanisms by which mycophenolic acid (MPA)—an immunosuppressant medication used by over 80% of lung transplant recipients—induces neutropenia, a serious adverse effect characterized by...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $814,387 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 1, 2025 through April 30, 2029, funds research investigating lung vascular Group 3 Innate Lymphoid Cell (ILC3) subpopulations and their roles in antibacterial immunity and vascular regeneration. The...